AZN

AstraZeneca (AZN) is the lead sponsor of 200 active clinical trials listed on ClinicalTrials.gov^[5], including 67 Phase 3^[1], 49 Phase 2^[2], 47 Phase 1^[3], 1 Phase 4^[4].

Trial NCT06471257^[6] evaluates Budesonide/Albuterol metered dose inhaler, MDI in Asthma with a target enrollment of 790 participants. Trial NCT07000136^[7] evaluates AZD0780 in Heterozygous Familial Hypercholesterolaemia with a target enrollment of 455 participants. Trial NCT03091192^[8] evaluates Savolitinib in Carcinoma with a target enrollment of 60 participants.

No Form 4 insider filings for AZN were recorded at the SEC in the past 30 days^[9].